Get access

Efficacy and safety of cefovecin (Convenia™) for the treatment of urinary tract infections in dogs



Objectives: To determine the efficacy and safety of cefovecin (ConveniaTM; Pfizer Animal Health) in the treatment of urinary tract infections in dogs.

Methods: A multi-centre, blinded, randomised study was conducted in 129 dogs with urinary tract infections. Cephalexin (RilexineTM) administered twice daily at 15 mg/kg bodyweight orally for 14 days was compared with a single, subcutaneous injection of cefovecin (ConveniaTM) in dogs. The primary efficacy parameter assessed was bacterial elimination of the pretreatment uropathogen.

Results: One hundred and twenty-nine dogs were included in efficacy assessments. Escherichia coli was eliminated in 90·5 per cent of cefovecin-treated dogs compared with 52·9 per cent of cephalexin-treated dogs (P=0·0004). Overall cure rates for dogs with Escherichia coli infections were 79·1 per cent for cefovecin and 36·4 per cent for cephalexin-treated dogs (P=0·0003). There were no suspected adverse drug reactions attributed to treatment with cefovecin or cephalexin.

Clinical Significance: Cefovecin was shown to be an effective and safe treatment for urinary tract infections.